Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Combinations Continue To Drive Immuno-Oncology Deal-Making

May 08 2017

• By Amanda Micklus

IV1705_Word-Cloud_I-O_1200x675

Related Content

Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing

Jan 20 2017

BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key

Mar 07 2017

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

Big Pharma Licensing Growth Slows In 2016

Mar 09 2017

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Amgen, Inc.

Bristol Myers Squibb Company

AbbVie Inc.

Roche Holding AG

Additional Topics

Deals ImmunoOncology Market Intelligence Cancer BioPharmaceutical

More from Deal-Making

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window